Documented incontinence after stroke: a secondary analysis of a cohort study. Reducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care).

Aim: To estimate the prevalence of incontinence after stroke in Aotearoa New Zealand overall and by ethnicity, the associations between incontinence and subsequent mortality and living in residential care, and to estimate the health utilities in relation to continence.

Method: Secondary analysis of data from a prospective (1 May to 31 July 2018) cohort study (REGIONS Care study) of patients with a confirmed stroke admitted to New Zealand hospitals. Logistic and linear regression were used, and multivariate models were adjusted for age, sex, ethnicity, and stroke severity.

Global Impact of COVID-19 on Stroke Care and IV Thrombolysis.

Objective: To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods.

Methods: We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases.

Cost-benefit of outcome adjudication in nine randomised stroke trials.

Background: Central adjudication of outcomes is common for randomised trials and should control for differential misclassification. However, few studies have estimated the cost of the adjudication process.

Methods: We estimated the cost of adjudicating the primary outcome in nine randomised stroke trials (25,436 participants).

Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials: A Systematic Review and Meta-Analysis.

Background and Purpose- In randomized stroke trials, central adjudication of a trial's primary outcome is regularly implemented. However, recent evidence questions the importance of central adjudication in randomized trials. The aim of this review was to compare outcomes assessed by central adjudicators with outcomes assessed by site investigators.

Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.

Background: Two antiplatelet agents are better than one for preventing recurrent stroke after acute ischaemic stroke or transient ischaemic attack (TIA). Therefore, intensive treatment with three agents might be better still, providing it does not cause undue bleeding.

Objective: To compare the safety and efficacy of intensive therapy with guideline antiplatelet therapy for acute ischaemic stroke and TIA.

Changes in the provision of transient ischaemic attack services in New Zealand 2008 to 2013.

Background: Urgent assessment and management of patients with transient ischaemic attack (TIA) reduces the early risk of stroke. In 2008 an audit was conducted of TIA services in New Zealand and a substantial discrepancy was found between clinical practice and recommendations in TIA guidelines. We aimed to re-evaluate the situation again in 2013 to determine if there had been any change in provision of TIA services.